Pipeline 2012 / Pharma´s Front Runners

Cardiovascular

-Dalcetrapib Roche

Indication: Atherosclerosis (Phase III)

-Eliquis (apixaban) Bristol-Myers Squibb/Pfizer

Indication: DVT; stroke prevention in Afib (Preregistration)

Infectious Disease

-BI-201335 Boehringer Ingelheim

Indication: Hepatitis C (Phase III)

-Integrase Single-Tablet Regimen “Quad”

(elvitegravir/FTC/TDF/cobicistat) Gilead

Indication: HIV (Preregistration)

Neurology

-BG-12 Biogen Idec

Indication: Multiple sclerosis (Phase III)

-Bapineuzumab Pfizer/Johnson & Johnson

Indication: Alzheimer’s disease (Phase III)

Oncology

-Pertuzumab Roche

Indication: Breast cancer (Phase III)

-Zaltrap (aflibercept) Regeneron/Sanofi

Indication: Metastatic colorectal cancer (Prereg.), metastatic prostate

cancer (Phase III)

Rheumatology

-Tofacitinib Pfizer

Indication: Rheumatoid arthritis/plaque psoriasis (Phase III)

-Fostamatinib (R788) AstraZeneca + Rigel

Indication: Rheumatoid arthritis (Phase III)

Other

METABOLIC

-Bydureon (exenatide long-acting release) Amylin

Indication: Type 2 diabetes (Prereg.)

ORPHAN DISEASE

-GALNS (BMN-110) BioMarin

Indication: MPS IVa, or Morquio A syndrome (Phase III)

Ver